Loading stock data…
$1.17-0.02 (-1.68%)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALX Oncology Holdings Inc. in the Healthcare sector is trading at $1.17 with a market capitalization of $278M. Wall Street consensus targets $4.60 (5 analysts), implying a +293.2% move over the next 12 months. The stock is currently near its 52-week low of $0.86, remaining 36.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.27M↑ | -$18.97M↑ | -$23.02M↓ | -$22.53M↑ | -$23.47M |
| Net Income | -$17.97M↓ | -$17.93M↑ | -$22.85M↓ | -$22.14M↑ | -$25.95M |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a ...